A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia
Latest Information Update: 27 Aug 2026
At a glance
- Drugs MK 1167 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 01 Jul 2026 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Termination Notes: Business reason
- 28 May 2026 According to Clinical Trials Information System this study is terminated early in Spain, Italy and Netherlands due to Sponsor Decision
- 16 Mar 2026 Status changed from recruiting to active, no longer recruiting.